Associations of lifestyle factors with amyloid pathology in persons without dementia

Background: The association between lifestyle factors and Alzheimer's disease (AD) pathophysiology remains incompletely understood. Objective: The aim of this study was to assess the association of alcohol consumption, smoking behavior, sleep quality and physical, cognitive, and social activity...

Descripción completa

Detalles Bibliográficos
Autores: Oomens, Julie E., Vos, Stephanie J. B., Maserejian, Nancy N., Boada, Mercè, Didic, Mira, Engelborghs, Sebastiaan, Fladby, Tormod, Van der Flier, Wiesje M., Frisoni, Giovanni B., Fröhlich, Lutz, Gill, Kiran Dip, Grimmer, Timo, Hort, Jakub, Itoh, Yoshiaki, Iwatsubo, Takeshi, Klimkowicz-Mrowiec, Aleksandra, Landau, Susan M., Jimenez Bonilla, Julio Francisco, Rodríguez Rodríguez, Eloy Manuel
Tipo de recurso: artículo
Fecha de publicación:2025
País:España
Institución:Universidad de Cantabria (UC)
Repositorio:UCrea Repositorio Abierto de la Universidad de Cantabria
Idioma:inglés
OAI Identifier:oai:repositorio.unican.es:10902/39097
Acceso en línea:https://hdl.handle.net/10902/39097
Access Level:acceso abierto
Palabra clave:Alzheimer’s disease
Amyloid
Amyloid biomarker study
Cerebrospinal fluid
Positron emission tomography
Lifestyle
Descripción
Sumario:Background: The association between lifestyle factors and Alzheimer's disease (AD) pathophysiology remains incompletely understood. Objective: The aim of this study was to assess the association of alcohol consumption, smoking behavior, sleep quality and physical, cognitive, and social activity with cerebral amyloid pathology. Methods: For this cross-sectional study, we selected participants from the Amyloid Biomarker Study data pooling initiative. We used generalized estimating equations to assess associations of dichotomized lifestyle measures with amyloid pathology. Results: We included 9171 participants with normal cognition (NC) and 2555 participants with mild cognitive impairment (MCI) from the Amyloid Biomarker Study. Of participants with NC, 58% were women, 34% were APOE e4 carrier, and 27% had amyloid pathology. Of participants with MCI, 48% were women, 47% were APOE e4 carrier, and 57% had amyloid pathology. In NC, cognitively active participants were less likely to have amyloid pathology (OR = 0.77, 95%CI 0.66-0.89, p < 0.001). In MCI, participants who had ever smoked or had sleep problems were less likely to have amyloid pathology (OR = 0.85, 95%CI 0.73-0.99, p = 0.029; OR = 0.62, 95%CI 0.45?0.86, p = 0.004). Conclusions: In NC, cognitive activity was associated with a lower frequency of amyloid pathology. In MCI, favorable lifestyle behaviors were not associated with a lower frequency of amyloid pathology. The results of the current study contribute to the broader evidence base on lifestyle and AD by further characterizing the role of lifestyle behaviors in AD pathology across different clinical stages.